1344
www.neurologiepropraxi.cz34080400107651332012142633073553814284484965465656086586857327828098518919109269661005
19156558020012657111166
HLAVNÍ4945200012670127198263336370
TÉMA5337200012657114204274
Trvalá252736001063066104140171213
imunomodulácia275636001061569109151191245286326367398440473490530
a3302360010638
trvalá335636001062965103140171213
imunosupresia358436001061669110151192225265300335367402419459
verzus405836001063668104139180212
rekonštitučná428636001063365101140182214247265297338373414454
terapia47563600106296197139174191231
sclerosis50023600106316697129165206239256288
multiplex530636001065192123152170204235267306
/33988040010732
Neurol.3475804001075593139165209227243
praxi.3734804001074672114152170186
2025;26(3):185-1913940804001074487128172185230272296340362378415454497523560598639
/46248040010731
NEUROLOGIE47018040010757101158205267310370429450493
PRO5216804001074591154
PRAXI5391804001074591148201221
LITERATÚRA34157001234978134189250318368438498567
1.3407400853648
AlSharoqi402740083415689127159180217257272
IA,688740083155670
Aljumah772740083415672109167199237
M,10237400835568
Bohlega11057400833574112128163202234
S,13537400833346
et14137400833356
al.1483740083314760
Immune15577400831472130168206241
Reconstitution1812740083357010314017834084008326496486123145160198236
Therapy5888400833371106127159198229
or8298400833758
Continuous9008400833976114135150187224262300326
Immunosuppression12388400831572129166204241268304343382403437463489504541579
for1830840083185577
the1919840083215994
Management3409400835486124155194228285320358379
of7319400833756
Active800940083407195110142176
Relapsing-Remitting988940083357085117155182196234272294330365422437459483498535574
Multiple15749400835492107129143182198232
Sclerosis18189400833365801141351713401040083264167
Patients?4211040083356789104139177199226251
A686104008341
Narrative7431040083447798120153174190222256
Review.101410400833570102118153204215
Neurol124310400834373109130165180
Ther.14341040083316999119130
2020;9(1):55-66.157610400833468101135148184203234249261296328351388423437
2.34011400853652
Bar-Or4081140083356889109159181
A,60511400834155
Grove67711400834465102134169
RA,8621140083357892
Austin97111400834178104127143180
DJ,11681140083456880
et126411400833456
al.13371140083314760
Subcutaneous141311400833370109142180202235273308347385411
ofatumumab1840114008338579011215034012400835794152184222
in57512400831552
patients6401240083387192107142179201228
with8811240083506587125
relapsing-remitting10191240083205470101140167181219257279301335392407429453468506544
multiple157612400835794109132147185201235
sclerosis.18241240083265873108129165340134008326416781
The43613400833372107
MIRROR55813400835570106142190226
study.8001340083264987126158168
Neurology.98413400834373109130165180215252281292
2018;90(20):e1805-e1814.128813400833468100131143179214234268302320332367396427463497519555585616648679692
3.34014400853651
Brod4121440083365795135
SA.5671440083337489
The67714400833272107
genealogy,80514400833873112147179195233273305315
methodology,114114400835793115154192232271287325365398407
similarities,15691440083264199115130163184200222238273300313
and190314400833270109
differences340154008339557695131153188228261296324
of68615400833858
immune76615400831574134173213249
reconstitution10371540083215690128168196220236259299322338378418
therapies14761540083226298120155195212248276
for17731540083195881
multiple187515400835998114340164008322397996132
sclerosis4951640083266076113135174202218245
and76216400833373113
neuromyelitis89716400833975115137176236269304321337360377404
optica.132316400833980103119153187201
Autoimmun15461640083397697134149207265303341
Rev.190516400833566982000164008313
2022;21(10):103170.34017400833468101136148183215230261293311323353384417448478511523
4.34018400853651
CAMMS22341118400834083138193226260294329
Trial760184008332506597113
Investigators,8921840083155384119146169184223255277314335363376
Coles12871840083407793128155
AJ,14621840083416880
Compston156118400834077136175201225262300
DAS,188118400834585119132
Selmaj3401940083326783140172187
KW,54019400833595104
et65719400833456
al.7261940083324760
Alemtuzumab7991940083405690148169207236274332364403
vs.12151940083315871
interferon12991940083155274107128149184205242280
beta-1a15921940083387496128151181209
in181419400831552
early18791940083346687102134
multiple34020400835795110133148187203238
sclerosis.5932040083265874109130167194209235248
N857204008343
Engl91220400833167103118
J1042204008324
Med.107920400835283119132
2008;359:1786-801.122720400833468104140152187220252265295325358393417453488520529
5.34021400853650
Clerico4082140083405590111127159196
M,62121400835467
Artusi7052140083416387125152166
CA,8882140083408397
Di100221400834561
Liberto10802140083314786121142167204
A,130121400834155
et137321400833456
al.14462140083324760
Long-term152321400833269107146169191225246305
safety18442140083276079113135169
evaluation3402240083346699115152184206221259298
of65522400833757
natalizumab7292240083387092125140155184222280312352
for10982240083185678
the11932240083226095
treatment13052240083224377109131189224262284
of160622400833857
multiple168022400835895111133148187203238
sclerosis.1936224008326583402340083155071108135150176189
Expert5452340083316197128148171
Opin7292340083458197133
Drug87523400834364101136
Saf.1024234008331668596
2017;16:963-72.113623400833468100129139169200213248283317339370405417
6.34024400853652
Cohen40824400834077115150189
JA,6132440083246478
Coles7072440083407793128155
AJ,8782440083416880
Arnold97424400834163101139155194
DL118524400834577
et127824400833457
al.13512440083324760
Alemtuzumab14272440083415791149171209238276334367406
vs.18492440083325972
interferon193824400831452340254008322557798133154191229
beta5832540083387496129
1a72525400833563
as80125400833259
first-line873254008317345582105125141156194229
treatment11162540083214377109130188223262283
for14122540083195678
patients15032540083397294109144182203231
with17472540083516789127
relapsing-remitting188825400832054701023402640083396580118157179201235293309331355371408447
multiple80226400835795110133148187203238
sclerosis:10542640083265974109130167194209235247
a1316264008332
randomised13632640083205392131169227242268303343
controlled172026400833168107128150187203218253292
phase34027400833977109136171
3526274008335
trial.576274008321435991106119
Lancet.70827400832964101130159181193
2012;380:1819-1828.91327400833468100130142177212247260290321353383407437468502536549
7.34028400853645
Coles4022840083407793128154
AJ,5742840083406880
Cohen67128400834077115150188
JA,8762840083246478
Fox97128400833370100
EJ,10892840083325971
et117728400833456
al.12502840083324760
Alemtuzumab13272840083415792149171209238277334367406
CARE-MS175028400834083119152174230263
II34029400831530
5-year3912940083345688122154175
follow-up:587294008318567287125177199238277289
efficacy897294008334527088120153186219
and113729400833170109
safety12662940083266079113136169
findings.14562940083173472111126164203229243
Neurology.172029400834373110130165180216252282293
2017;89(11):1117-1126.34030400833468100129139174209228260287302314343371399428447477505535569582
8.34031400853652
Coles4093140083407793128154
AJ,5813140083416880
Twyman67831400833380114172205243
CL,9383140083407285
Arnold104131400834162101139155194
DL,12523140083457891
et136131400833456
al.14343140083324760
Alemtuzumab15123140083415691149170208238276334366405
for19353140083185677
patients3403240083397293109143181203231
with5873240083516789127
relapsing7313240083215570102142168183221260
multiple100832400835795110132148187203238
sclerosis12623240083265974109130167194209235
after15143240083315075109130
disease-modifying166132400833853791141461732082312903283403340083385372107123161200
therapy:5593340083226095116149188219233
a811334008332
randomised8583340083215492131169227243269304343
controlled122133400833168106128149186202217252292
phase153233400833977109136171
31722334008335
trial.1776334008321435991106119
The19143340083316898
Lancet.34034400832964101130159181193
2012;380(9856):1829-1839.54634400833468100130142177212247267299334368402420432462493527561584615646680713724
9.34035400853649
Comi40535400834077135150
G,57135400834457
Cook64435400834077116146
S,80635400833346
Rammohan86735400833669126184223261293331
K,121435400833550
et128035400833456
al.13523540083324760
Long-term142835400833169107146168191225246304
effects17483540083345473107140164191
of195535400833857
cladribine3403640083314779118139155194209247282
tablets6363640083225494109144167194
on84436400833776
MRI93436400835490106
activity10543640083316488103136151174207
outcomes12753640083387698129166224259286
in157536400831452
patients16413640083397293109143182203231
with18863640083506688126
relapsing-remitting3403740083215570103142168183221260282304339396412434458474512551
multiple90637400835895110133148187203238
sclerosis:11603740083265873108129167193208234247
the14223740083226095
CLARITY153337400834071114150166200239
Extension1788374008332658912316118720234038400833776
study.4283840083264987126158168
Ther6073840083316898119
Adv73638400833873103
Neurol85038400834373109129164179
Disord.10403840083435982117138172185
2018;11:175628561775(3365).123638400833468100131143173200209238268300334368401435469499529563596613647680714748766777
10.3403940085367085
Comi44639400834078136152
G,61839400834458
O’Connor69639400834861101139178216255276
P,99339400833540
Montalban105439400835493132154187202242275313
X,138839400833952
et146139400833456
al;15383940083324859
FTY720D2201161839400833368108144178213260292327362394
Study3404040083325492131163
Group.52340400834465102141180192
Phase73640400833572104131166
II92240400831530
study9734040083264987126158
of115140400833857
oral12284040083375992107
fingolimod13564040083173472111149165180237276315
(FTY720)16924040083185186125161195229247
in196040400831452
multiple34041400835794109131146185200235
sclerosis:5874140083265873108129165192206232244
3-year8444140083345587121152173
results.10304140083205480117132154181195
Mult123741400835288103123
Scler.13704140083316074104125135
2010;16(2):197-207.15164140083346899130143172203222255273285314344376394425459491497
11.3404240085356476
Confavreux42842400833975113131163194215248285315
C,75542400833951
O’Connor8184240083475998134171208245266
P,109642400833539
Comi114742400833975132146
G,130542400834356
et137342400833355
al.14404240083314658
Oral15104240083466799114
teriflunomide1636424008321547489106123159196233290305343376
for3404340083185677
patients4304340083397293109143181203230
with6734340083516688126
relapsing8124340083215570103142168183221260
multiple108543400835794110132147186202237
sclerosis13344340083275974109130167194208234
(TOWER):158143400831954101158192227246258
a1852434008331
randomised,1899434008320539134044400833774131145170204242254
double-blind,60644400833774111149164198220259274288325362374
placebo-controlled,9924440083385384115148186223246278314351372392428443458491530542
phase154544400833875107132166
31723444008333
trial.1768444008321415687102114
Lancet189444400832862983404540083295778
Neurol.42845400834373108128163177190
2014;13:247-56.6294540083346799129141170200211245277308326360394407
doi:10.1016/S1474-4422(13)70308-9.10484540083387591102132163175205236267298323355385416447477500536572604638655687716733764796829863898920954965
12.3404640085366884
De44046400834581
Sèze5374640083336897131
J,68546400832436
Suchet73846400833270102140175197
L,95246400833145
Mekies,101446400835489119136170197210
C.124146400834053
et131146400833456
al.13844640083314760
The146046400833372107
Place15844640083355082114148
of174846400833857
Immune18224640083147213016834047400833874
Reconstitution43547400833672105143183210233249272311334350389428
Therapy88447400833374109131165205237
in114247400831554
the12174740083226197
Management133547400835689128161201237296332371393
of174947400833858
Relapsing182847400833672881211613404840083264179118
Multiple47248400835492107130145184200235
Sclerosis7214840083326480114136173200214241
in97548400831553
France:10424840083325285123155189201
An125748400834179
Expert135048400833265104140161186
Consensus.155048400834077115141176214241278304318
Neurol1882484008343731093404940083205570
Ther.4234940083306898119129
2023;12:351-369.56549400833468101136147177207220255288319338370405439450
13.3405040085366782
Förster4345040083326990117139173193
M,64050400835467
Graf7195040083436597116
J,84750400832436
Mares89550400835486107140166
J,107450400832436
et112250400833455
al.11905040083314659
Drug126150400834566104142
treatment14165040083214276107128186220258279
of170750400833756
clinically1775504008331466198113144177192206237
isolated340514008315417995127149183222
syndrome.5775140083275998137158195254289301
CNS89351400833880110
Drugs.101651400834365101136160174
2019;33:659-676.120351400833468100130143178211222258292324347385417449463
14.3405240085366984
Giovannoni4425240083445997129162200238276315330
G,79052400834457
Comi86552400834077135151
G,103452400834357
Cook110952400834077116146
S,127352400833346
et133752400833456
al.14115240083324760
A1489524008341
placebo-controlled154652400833854861181521912302542873243633844064433405340083153066106
trial467534008322446092108
of59653400833857
oral6745340083386093109
cladribine8045340083324780120141157197213251287
for11125340083185779
relapsing12125340083215571104144171186225264
multiple149753400835896112135150190206242
sclerosis.17605340083265975110132170197212239252
N340544008343
Engl39554400833167103118
J525544008324
Med.56254400835283119132
2010;362:416-26.71054400833468100131144179214247260294324356379410444457
doi:10.1056/NEJMoa0902533.11825440083387692104134165178209240274308333379413439494532565601636672705740773806818
15.3405540085366883
Giovannoni4395540083445997129162200238276315330
G,78555400834457
Soelberg85855400833371106122161197218256
Sorensen11305540083327192126164191226264
P,141055400833540
Cook146655400834077115146
S,162855400833245
et168955400833456
al.17615540083324861
Safety18385540083326584118141174
and34056400833270109
efficacy469564008334527088120153185218
of70756400833757
cladribine7835640083324779118139155194210248283
tablets10855640083225594110145167195
in130056400831452
patients13725640083397293109143181203231
with16225640083516789127
relapsing-remitting176956400832155701031421681832213405740083386082116174189212236252289328
multiple68557400835795110133148187203238
sclerosis:9395740083265974109130167194209235247
results12035740083215581119134156184
from14045740083184077136
the15565740083226095
randomized16675740083215492131169228243272306345
extension3405840083346590124162188203241279
trial632584008322435991106
of75158400833757
the8215840083215994
CLARITY92858400834072115151167201240
study.11815840083264987126158168
Mult136258400835389104124
Scler.14975840083316075105126136
2017;24:1594604.16445840083346810012913917420621824827831034634059400833470106118
doi:4745940083387691104
10.1177/1352458517727603.5935940083346578109136166200220254283316350381414448482513543577612645677712745758
16.3406040085366985
Harding4386040083447698136151189228
K,67960400833549
Williams7416040083587489104119151209235
O,98960400834758
Willis10606040083587489104119145
M,121860400835568
et129960400833456
al.13686040083324760
Clinical14416040083405570108123155188203
outcomes16576040083387698129166224259286
of195660400833757
escalation3406140083336091123138169190205242279
vs63261400833157
early7016140083336585100131
intensive8446140083155273105143168182214248
disease-modifying11046140083375277111142168202225282319358373391425440477515
therapy16316140083215993113145184214
in185761400831552
patients1921614008338703406240083223772110131159
with5146240083516689127
multiple65662400835895111133148187203238
sclerosis.9096240083275974109130167194209235249
JAMA117362400832461114152
Neurol.133862400834373109130165180193
2019;76:536-541.154662400833468100130143176208220256289323346380416446455
17.3406340085366776
Hauser42963400834476113139174195
SL,6366340083336377
Bar-Or7256340083366889109158180
A,91763400834155
Cohen98563400833976114149186
JA,11846340083246478
et127463400833456
al.13436340083314659
ASCLEPIOS141563400834074114146178213228275307
I1735634008315
and176563400833169108
ASCLEPIOS18856340083417511534064400833165100114162195
II55064400831430
Trial594644008333506698113
Groups.72264400834465102141180206220
Ofatumumab95764400834767101122160218256314346385
versus13576440083326687114151178
Teriflunomide15506440083326384100117134172210248306322360395
in196064400831553
Multiple21407400835492108130145184200235
Sclerosis.2390740083336581115137174201215241255
N266174008343
Engl27167400833167103118
J284674008324
Med.28837400835283119132
2020;383(6):546-557.30287400833468101135148183217251270303321333368403439463497529563569
18.2140840085366985
Hauser22388400834476114140175196
SL,2447840083326377
Bar-Or2537840083356889109159180
A,27308400834155
Comi27988400834077135150
G,29618400834457
et30318400833456
al.3100840083324760
Ocrelizumab31738400834780101135150165194232290322362
versus3548840083316586114151177
interferon37388400831552214094008322557798133154191229
Beta-1a2384940083357093125148179207
in26069400831452
relapsing2673940083205470102141168183221260
multiple29479400835895111133148187203238
sclerosis.3199940083275974109130167194209235249
N346294008343
Engl35179400833166102117
J364694008324
Med.36829400835283119380094008312
2017;376:221-34.214010400833468100129139174206238251286321352371403438451
doi:26061040083387792104
10.1056/NEJMoa1601277.27251040083356679109141175209234280313340395433466496527563595624657692698
19.21401140085366982
Havrdova224011400834476108130168206238271
E,252911400833245
Douglas259211400834584122161176209235
DL,28451140083457791
Cohen295311400834077116151189
JA,31601140083246478
et325511400833457
al.33291140083324760
Alemtuzumab34071140083415691149171209238276334366406
CARE-MS214012400834082118152173229262
I2415124008314
5-year24451240083345687122153174
follow-up.2632124008319567287125176198237276288
Durable293312400834583104137176192227
efficacy3173124008334527088120152184218
in340412400831452
the34691240083216094
absence35761240083327198133171203236
of214013400833757
continuous221213400833168106128143181219257295321
MS254913400835487
therapy.26511340083226095116149189220230
Neurology.289613400834373109130165180215252281292
2017;89(11):1107-1116.320113400833468100129139174209228260287302314343371402435454484512540571584
20.21401440085367287
Heckova224114400834479112142179211244
E,249914400833346
Dal-Bianco25591440083457793115152167199238270307
A,288014400834155
Strasser29491440083325375108134161196217
B,318014400833548
et324214400833456
al.33121440083324760
Extensive33861440083336690124162188203235270
Brain36701440083355689105142
Pathologic21401540083356789127165181219259274306
Alterations24631540083415779113134167189204242281307
Detected278815400834580102136169193227266
with30721540083506688127
7.0-T3216154008334407599129
MR336315400835490
Spectroscopic34711540083327110713916318522224928131821401640083395587
Imaging224816400831574107146162200240
Associated25091640083416996135169184216239273313
with28431640083516790128
Disability29921640083466289122162178193209232266
in327916400831453
Multiple335316400835593109132147187203239
Sclerosis.361216400833366821171391772140174008326416781
Radiology.223417400833470105120156171207243272284
2022;303(1):141-150.252817400833468101136148183218251269300315327357388418437467497532544
doi:30851740083387692104
10.1148/radiol.210614.32021740083346678109136168204229248281320336373389402438470501537567598611
21.21401840085366982
Ingwersen22351840083155392143177198226261299
J,254718400832436
Aktas25961840083407195128154
O,276318400834758
Hartung28341840083447798122160198237
HP.30841840083448085
Advances318218400834179111144182214248275
in347018400831452
and353518400833270109
Algorithms365718400834156951332140194008321365896153179
for23321940083185577
the24211940083226094
Treatment25281940083324983114136193228266287
of282819400833756
Relapsing-Remitting28961940083367086117156183197235273295332367424439461485500538576
Multiple348519400835491107129144182198232
Sclerosis.37301940083326421402040083155071108135150176189
Neurotherapeutics.234520400834373109130165185222252272306342373409430444474499513
2016;13(1):47-57.287320400833468100131143174204222253268280314346365399432438
22.21402140085377490
Kappos225221400833570110151190218
L,249121400833246
Antel255821400834281103138154
J,273321400832537
Comi279221400834078138153
G,296621400834559
et304621400833558
al;31252140083324860
FTY720320621400833369109146181216
D2201344321400834680115150183
Study36472140083335594134166
Group.214022400834465103141180193
Oral235322400834769102118
fingolimod24912240083173472111149165180238277316
(FTY720)28282240083185186125161196230248
for30972240083185678
relapsing31952240083215571103142169184222261
multiple347622400835895111133149188204239
sclerosis.37352240083265921402340083155071108135150176189
N2345234008343
Engl240023400833167103118
J2530234008324
Med.256723400835283119132
2006;355(11):1124-1140.271223400833468104140152187220253271302330344356386414444475498529557588624636
23.21402440085367287
Kappos224624400833568108147186213
L,247724400833145
Bar-Or25402440083366990110160181
A,274024400834155
Cree28132440083406195131
BAC,296224400833576115128
et310824400833457
al.31832440083324760
EXPAND326124400833373108146191237
Clinical35162440083405570108123155188203
Investigators.37382440083145221402540083316592115130169201222259280307320
Siponimod24732540083324786124162177235273312
versus27972540083326687114151177
placebo29872540083385486117151190228
in322825400831552
secondary32932540083266093129168206238259293
progressive3599254008338599613615719021402640083265368100134
multiple229126400835795110132148187203237
sclerosis25452640083265873108130167193208234
(EXPAND):27962640083185191126164209255273284
a3097264008332
double-blind,314426400833876114153169204227267283298336375388
randomised,35482640083215492131169227242214027400832662103116
phase227727400833978111138174
32472274008335
study.25282740083265089129161172
Lancet.271727400832965103133162184197
2018;391(10127):1263-1273.293227400833569102134146182216249264297329361392425445458488519553588610642672706741754
doi:37072740083387793106
10.1016/S0140-6736(18)30475-6.21402840083346678109140172203228261296328359395419456489523558577608639657690725761793826848885899
24.21402940085367186
Kappos224429400833568108147186213
L,247529400833145
Fox253829400833270100
RJ,26562940083366274
Burcklen27492940083357394125155172207245
M,301229400835468
et309829400833456
al.31722940083324760
Ponesimod325029400833572111146172187245283323
compared35912940083316812616619921403040083215595
with22563040083506689127
teriflunomide2404304008322567793111128165204242301316355391
in281530400831553
patients28893040083387294109144182204232
with31423040083516689127
relapsing32903040083215571103143170185223262
multiple357330400835795111133149188204239
sclerosis21403140083265974110131169196211237
in239831400831553
the24723140083216095
active-comparator25883140083326589104137172195229267325365398420453475512534
phase314331400833978110137173
33336314008335
OPTIMUM339131400834884118135190235290
study:3702314008326508821403240083387084
a2238324008332
randomized22863240083205391130168227242271305345
clinical26453240083324762100115147180195
trial.2855324008322435991106119
JAMA298932400832461114152
Neurol.315432400834273109129164179192
2021;78:558-567.336132400833468101133141174207219255287321344378412445451
25.21403340085367287
Kappos224133400833568108147186213
L,246833400833145
Radue252733400833568107145179
EW,272033400833392102
O’Connor283633400834760100137175213252273
P,312333400833540
et317733400833456
al;32473340083324759
FREEDOMS332033400833368101134179228283316
Study36503340083325391130162
Group.214034400834465103141180192
A2348344008341
placebo-controlled24053440083385486119152192230254287324363384406443459474509548
trial2969344008322435991106
of309134400833857
oral31643440083375992107
fingolimod32873440083173472111149165180238276316
in361934400831552
relapsing3687344008321557110321403540083386580117156
multiple230935400835794110132147186202236
sclerosis.25583540083265873108129166192207233246
New281535400834373122
Engl294735400833167102117
J3074354008324
Med.310935400835283118132
2010;362(5):387-401.32543540083346899131143178212246263296314326361395428446483518550559
26.21403640085367288
Kappos224836400833569108148187214
L,248236400833245
Wolinsky254836400835894110125163190220254
JS,28223640083255770
Giovannoni29123640083446098130163201239278316332
G,326436400834457
et334236400833457
al.34193640083324760
Contribution350036400834077116137159175214252275290214037400833776
of223437400833757
relapse-independent23093740083205570102141168203226242280319354393429467506541579601
progression29283740083396097137158192219246260298337
vs328337400833259
relapse-associated3360374008321557010314216820322725928531235038339843021403840083225595
worsening225038400835188110137172210225263302
to256738400832259
overall264138400833769104125158173188
confirmed284438400833268107124141162221256295
disability31553840083385379112151167182197219253
accumulation34233840083326495133191228244276298313351389
in214039400831553
typical22073940083225595111143176191
relapsing24133940083205470102141168183221260
multiple268739400835895111133148187203238
sclerosis29403940083265873108130167193208234
in318939400831552
a3256394008332
pooled330339400833978116132167207
analysis352439400833270102118149176191217
of375639400833756
22140404008334
randomized21894040083215492131169228243272306345
clinical2550404008331466199114146179194
trials.2760404008321435890106132145
JAMA291840400832461114152
Neurol.308340400834373109130165180193
2020;77:1132-1140.329140400833468101135148181215226255283313345366397424455491504
27.21404140085367180
Kavaliunas223441400833568100133148163201239271298
A,254641400834155
Manouchehrinia261541400835587125164202234272307345366382420435467
A,309641400834155
Stawiarz31664140083325386137152184205236
L,341641400833245
et347641400833456
al.35464140083324760
Importance36214140083147211115017221404240083225593126160
of232042400833857
early23984240083346788104136
treatment25554240083214378110132190226264286
initiation2862424008314536891106138160176214253
in313642400831553
the32094240083226196
clinical33264240083314762100115148181196
course354342400833269107129156192
of375542400833857
multiple214043400835795110133148187203238
sclerosis.23934340083265874109130167194209235248
Mult265743400835389104124
Scler.27944340083316075105126136
2017;23:1233-1240.294343400833468100129139174209220250280315348370400430462498511
28.21404440085367288
Leist22444440083316681107130
TP,23904440083326974
Comi248044400833976135150
G,264644400834357
Cree27194440083406195130
BAC,286544400833576115128
et300944400833456
al.30814440083324760
Effect31574440083335271105138162
of333544400833756
oral34074440083385992108
cladribine35304440083324779118139155194210248283
on214045400833776
time22354540083213794129
to238345400832259
conversion246145400833168106138172193221235273312
to279245400832158
clinically28694540083324762100115147180195210242
definite31304540083387390107145160183216
multiple336545400835895111133148187203238
sclerosis3622454008326587410913016721404640083264167
in222246400831553
patients22904640083387193108143181203230
with25354640083516789127
a2677464008332
first2724464008317345582106
demyelinating284546400833873130161196211226264296318333371410
event327046400833467101139160
(ORACLEMS):344546400831965102145184215248304337356367
a2140474008332
phase218747400833977110136171
32373474008335
randomised24234740083215492131169227242268303343
trial.2781474008322435991106119
Lancet291347400832964101130159181
Neurol.310647400834373109130165180193
2014;13:257-67.331147400833468100131143173203214249284318336373406412
29.21404840085367184
Lisý22374840083314672104
Ľ.235348400833245
Individualizácia24104840083155391106138153192229261276290319352384399430
pacienta285348400833870102117151189210242
pri31084840083385975
výbere319548400833265105140160194
vhodnej340248400833169107146183218233
liečby3647484008315306496135165
sclerosis21404940083265874109130167194209235
multiplex.239049400835795110133148187203238269283
Via26894940083355085
pract.27874940083355690120142154
2016;295349400833468100131143
13(5):191-194.31124940083346482116134146176206238257287318353366
30.21405040085367287
Lünemann224650400833168106141199232270308
JD,25725040083247081
Ruck267250400833573105135
T,282650400833241
Muraro288650400835492113146167205
PA,31095040083357387
et321450400833456
al.32895040083324760
Immune336850400831472130168206241
reconstitution362750400832155881251632140514008326496587125148163201239
therapies:23995140083226095116149188204239266278
concepts269751400833168107139172212234261
for29785140083195678
durable30765140083387697130169185220
remission331651400832054112127154180195233271
in360751400831553
multiple3680514008357951102140524008322377692127
sclerosis.22845240083265873108129166193208234248
Nat25495240083437999
Rev26625240083346495
Neurol.277052400834374110130165180193
2020;16(1):56-62.298052400833468101135148178209228260274286322356379417450463
doi:34595240083387792104
10.1038/35805240083346578109140173208233
s41582-019-0268-z.21405340083266292122157190211248280310333370403437472495522536
31.21405440085366981
Mallucci223954400835487102117155187218233
G,248954400834457
Annovazzi256354400834179117156188221250281297
P,287754400833540
Miante293454400835470102140161195
S,314654400833245
et320854400833456
al.32815440083324860
Two-year335854400833380118141173207239260
real-life36355440083215587102125141156214055400831853
efficacy,2206554008334537088120153185219229
tolerability24485540083225974109130163203218233248271305
and276655400833270109
safety28885540083265978113135169
of307055400833757
dimethyl314055400833853111146168207237253
fumarate340755400831857114147168201223256
in367755400831452
an374355400833270
Italian2140564008315377085100132170
multicentre232656400835794110132147179213251273294328
study.26705640083264987126158168
J2853564008324
Neurol.289056400834273109129164179192
2018;265:1850-9.309556400833468100131143178212246256286317351385409444455
32.21405740085367289
McGuigan224857400835488135174191231265304
C,257157400834054
Craner26445740083406297136173195
M,285857400835570
Guadagno294757400834383116157191231270310
J,327657400832438
et333357400833457
al.34095740083324963
Stratification34915740083335578112135152173190224258281298214058400833777
and223658400833171111
monitoring236658400835797137153177215238255295335
of271958400833858
natalizumab-associated27965840083377194128145162192232291325365390424452480519554570603627662703
progressive351758400833962100141164199228256272214059400833267
multifocal222959400835796113137154174213247282298
leukoencephalopathy25495940083155190122161198237271306346386420437476517552575614647
risk:3217594008321386597113
recommendations33525940083205690128188247283323363397420437214060400833777105
from22676040083194281140
an243060400833271
expert252360400833467108145168194
group.273960400833861100139180193
J2955604008324
Neurol299860400834374112134170187
Neurosurg320360400834375113134171196232254290
Psychiatry.35126040083335990120158174211233255288300
2016;87:117-25.214061400833470103135149186220232263292323343375411425
33.21406240085367186
Miclea223962400835470102117152184
A,243662400834155
Leussink250562400833165103129156171209239
VI,27576240083365265
Hartung28356240083447798122160198237
HP,30866240083448084
et318362400833457
al.32536240083324760
Safety33266240083336685119142175
and351562400833169109
efficacy3637624008334527088120153214063400833165
of222063400833756
dimethyl229163400833853111146168207237253
fumarate255963400831957115147169202223257
in283163400831553
multiple289963400835795110132148187203237
sclerosis:31516340083265974109130167194209235247
a3413634008332
multi-center346063400835895111133148171204238276297331352
observational214064400833777104139160195227249264302341373389
study.25446440083264987126158168
J2728644008324
Neurol.276564400834273109129164179192
2016;263:1626-32.297064400833468100131143178212246257287318351385409441473486
34.3940740085367388
Minneboo40447400835470108146181220259298
A,43577400834155
Barkhof4427740083356889120159197217
F,46597400833238
Polman4712740083357288146178216
CH,4943740083408497
Uitdehaag5055740083445981119154192225257296
BM,53667400833590104
Knol54857400833574112128
DL,3940840083457689
Castelijns4042840083397197120153168182197234260
JA.4314840083246377
Infratentorial440484008314517091124145178215236272293308340354
lesions477184008314487589126164190
predict4973840083385992131146177201
long-term5186840083145289128149171204225282
disability5481840083375277110394094008339546984107141
in40989400831452
patients4167940083397294109144182203231
with4415940083516689127
initial455994008315536890106138153
findings4729940083173472111126164203229
suggestive49759400832764103142177204227242275309
of53019400833757
multiple53759400835795110132148187203238
sclerosis.39401040083265874109130167194209235248
Arch42041040083385887123
Neurol.434010400834273109129164179192
2004;61(2):217-221.454510400833468104141152188219234267285297332364393412443478509518
35.39401140085367287
Montalban404811400835594133155189205244278316
X,438511400833953
Hauser445911400834477116142178200
SL,46801140083336478
Kappos477911400833670110150189217
L,501711400833145
et508311400833558
al.51621140083324861
Ocrelizumab524411400834781102137153168198237296329369
versus39401240083326890118156184
placebo41451240083395689123157198238
in440412400831554
primary44801240083396278137171193228
progressive472912400834062101141163199226254269303338
multiple508912400835897113136152193209245
sclerosis.53561240083266076112134172200215242257
N3940134008343
Engl399313400833167102117
J4120134008324
Med.415513400835283119132
2017;376:209-20.429813400833468100129139173205237249284318353377408441454
doi:47651340083387691103
10.1056/NEJMoa148811340083346578108140174208233278311338392431464493
606468.538713400833469105141177212226
36.39401440085367389
Newsome405014400834581133160199258294
S,436514400833245
Krzystanek44311440083365890124152175209247283314
E,476514400833347
Selmaj48331440083336884143175191
K,504514400833550
et511614400833457
al.51941440083324861
Subcutaneous527614400833371111144182205238277313394015400833775102
ocrelizumab40621540083376991125140155184223281313352
in443415400831552
patients45061540083397294109144182203231
with47571540083506689127
multiple490415400835795110132148187203237
sclerosis:51611540083265974109130167194209235247
results54281540083215582119134157184
of394016400833757
the40141640083226095
phase412716400833877109136171
III43151640083153046
OCARINA437816400834788131167183228269
II466516400831530
study.47121640083275088127159169
J4898164008324
Neurol493616400834374110130165180
Neurosurg513116400834273109129164188223244278
Psychiatry.5423164008334588711715316839401740083355676108119
2024;95:A14.407217400833468101133145180214225268297328341
37.39401840085367079
O’Connor404018400834760100137176214252274
P,433418400833540
Wolinsky439418400835894110125163190219253
JS,46681840083245669
Confavreux475718400834077116135168200222256294325
C,510218400834053
et517618400833456
al.52521840083324861
Randomized533318400833568106145184242257394019400832862101
trial4054194008321435890105
of417219400833756
oral42401940083385992107
teriflunomide4359194008322557692109126164201239297312351385
for47571940083185677
relapsing48471940083205469101140167181219258
multiple511719400835795110132147186202236
sclerosis.53661940083265873108129166192207233246
N3940204008342
Engl399220400833166101116
J4118204008323
Med.415120400835383118131
2011;365:1293-303.42922040083346798125133168201235245274303337369390422456488501
doi:48052040083377590102
10.1056/NEJMoa1014656.49192040083346477107138171205229274307333387424457486517548578614647681693
38.39402140085367288
Polman40442140083357288145178216
CH,42752140083408597
O’Connor438821400834760100137176214252274
PW,467721400833593103
Havrdova479621400834476108130168206238271
E,508321400833245
et514421400833456
al.52162140083324760
A5292214008341
randomized,5348214008321549213116922724239402240083286199111
placebo-controlled40622240083385384115148186223246278314351372392428444458491530
trial4603224008322425788102
of471722400833655
natalizumab47832240083376889121135150178215271302340
for51352240083185475
relapsing5221224008320536899137163177214251
multiple5484224008356921073940234008322377692127
sclerosis.40822340083265874109130167194209235248
N4346234008343
Engl440123400833167103118
J4531234008324
Med.456823400835283119132
2006;471323400833468104140152
354:899-910.488123400833467102114149183219242277309341353
39.39402440085357083
Rommer403524400833572129186220241
PS,42882440083346679
Milo43792440083536883120
R,451124400833549
Han457224400834375112
MH,469624400835497110
et481824400833355
al.48852440083314658
Immunological495624400831471127164201239254291330344375408422
Aspects539024400834168106141172196223
of394025400833757
Approved401325400834181120142179211245285
MS431525400835487
Therapeutics.441925400833272107128161200236273296311343371384
Front48202540083314984121141
Immunol.497525400831470126162199234250263
2019;10:1564.525225400833468100130143173205218247278312348361
doi:39402640083387692104
10.3389/fimmu.2019.01564.40592640083346678114147181215239257274331389427440476510542572583618650680714751763
40.39402740085367489
Ruggieri405027400833674113152168203224240
S,431127400833245
Quartuccio437727400834786118140164203235266282320
ME,471827400835488101
Prosperini48402740083355694121160196217233271287
L.514727400833246
Ponesimod521327400833673111147174189247286326
in555927400831553
the39402840083226095
Treatment40542840083335084116138196231269290
of436428400833756
Relapsing44402840083357086118157184198236275
Forms47352840083326991149176
of493028400833757
Multiple500628400835492108130145184200235
Sclerosis:52602840083336581115137174201215241254
An553328400834179
Update394029400834483122155176210
on416729400833775
the42592940083226095
Emerging437129400833290125146184199237276
Clinical46642940083405570108123155188203
Data.48842940083457799132145
Degener504629400834475111141178208229
Neurol528829400834374110130165180
Neuromuscul548229400834373109394030400832055111147171200235250
Dis.4203304008344598396
2022;12:61-73.431530400833468101136148178208221256286305336371383
41.39403140085366880
Rudick403231400833572111125157186
RA,42313140083357791
StuartWH,43343140083335391122143167225270282
Calabresi46293140083397186118157178211238252
PA,48943140083347185
et499131400833456
al.50593140083324759
Natalizumab51313140083447697129144159188225282314353
plus54963140083395491117
interferon39403240083155375109130152187208246285
beta-1a42453240083397597131153184213
for44793240083185678
relapsing45783240083205571103143170185223262
multiple486132400835896111134149189205240
sclerosis.51223240083265874109130168195210236250
N5393324008343
Engl545332400833167103118
J5588324008324
Med.394033400835383119133
2006;354:911-23.408533400833468104140152187220256268303335363381412447459
doi:45603340083387691104
10.1056/NEJMoa044396.46793340083346678109140174209234280313339394433466501538574607640676689
42.39403440085367086
Rush40453440083357399137
CA,42013440083408296
MacLean431634400835487119151185217255
HJ,45893440083446981
Freedman46893440083325286121161219251289
MS.499734400835487100
Aggressive511634400834179118139173200227242274308
multiple54433440083579511013214839403540083395589
sclerosis:40463540083265874108130167194208234247
proposed43093540083396198137176203238278
definition46033540083387391107145160183198236275
and489435400833270109
treatment50193540083224377109131189224262284
algorithm.53193540083324886125146162184222280294
Nat39403640083437999
Rev40523640083346495
Neurol.415936400834373109130165180193
2015;11:379-389.436536400833468100130141171199207242274308331364398432443
43.39403740085367287
Selmaj40473740083336884141174189
K,425737400833550
Cree43273740083406296131
BAC,447937400833677116129
Barnett46293740083356890128164186210
M,486037400835568
et494937400833456
al.50263740083324760
Multiple510737400835593108131146185201236
sclerosis:53643740083265974109130168195210236248
time39403840083223795130
for40903840083185677
early41873840083346687103135
treatment43423840083224377109131189224262284
with46463840083506688127
high-efficacy47933840083375291129151188206224242274307339373
drugs.51863840083385997136162176
J5379384008324
Neurol.541938400834374110130165558538400831528
2024;271(1):105-115.394039400833468101133145180213245260292306318348380414436466494524536
doi:44913940083397792104
10.1007/s00415-023-11969-8.46113940083346578109140176209229253288324360391421443480513548570600628658694728751787800
44.39404040085367490
Sellner4048404008332688398136171192
J,425840400832437
Rommer431340400833573131189224246
PS.45774040083356881
Immunological467640400831573130168206244260298338353385418433
consequences512740400833268107133168208245280318351384411
of555640400833757
„immune39404140083203694151188226261
reconstitution42144140083205487123161187210226248286308323361399
therapy”46264140083215994115148187218240
in487941400831552
multiple494441400835795110132147186202236
sclerosis:51934140083265873108129166192207233245
A5451414008341
systematic55074140083265885394042400832255113146167183215
review.41704240083215587103137189199
Autoimmun43854240083387394128144199255291328
Rev.47254240083346595105
2020;102492.484342400833468101135148178210243274308341353
45.39404340085367186
Sorensen40404340083327192126165191226264
PS,43174340083356881
Lisby44114340083324773112144
S,456843400833245
Grove462643400834466103135169
R,480943400833549
et487143400833456
al.49414340083324760
Safety50144340083336685119141175
and520243400833270109
efficacy5325434008333527088120153185218
of555743400833756
ofatumumab39404440083375688110147204241298330368
in432044400831552
relapsing-remitting43844440083215469101139166180217256277299332389404426450465502540
multiple493644400835794109131146184200234
sclerosis:51824440083265872107127164190205230242
a5437444008331
phase548344400833876107394045400832661
24016454008335
study.40664540083264987126158168
Neurology.425045400834373109130165180215252281292
2014;82(7):573-81.455445400833468100131143178212229264283295330364398420456488497
46.39404640085377794
Stüve40614640083335696130167
O.425546400834861
The434346400833374111
effects44814640083355676112147172202
of471046400833859
natalizumab47964640083387296130147163194234295329370
on519346400833879
the52994640083226299
innate54254640083155595129152188
and394047400833271111
adaptive407247400833272105145167183216251
immune434447400831574133171210246
system46114740083265987111145204
in483647400831553
the49104740083226197
central502847400833266105127149183198
nervous52474740083387496131170209235
system.55034740083276088394048400832256114127
J4088484008324
Neurol412948400834373110130165181
Sci.4327484008330607588
2008443648400833469105141
Nov459748400834584116
15;274(1-2):39-41.47334840083356576111144175194226245276294306341375399435466475
doi:52294840083387792104
10.1016/j.53544840083346679110141173204230246259
jns.2008.03.022.3940494008315537993129163199235248283316329364397431444
47.39405040085367079
Stüve40395040083325492124158
O,421750400834758
Marra429450400835587109130163
CM,447750400834095108
Bar-Or46055040083356889109159181
A,480550400834155
et488050400833456
al.49555040083324861
Altered50355040083415679113134168207
CD4+/CD8+526250400834085121165189228273308351
T-cell39405140083325082115130145
ratios4097514008320527388125150
in425951400831552
cerebrospinal43235140083306384117155176212238276291328359374
fluid4709514008316336984122
of484351400833655
natalizumab-treated49105140083376889121136150178216272304342364386407440471492525563
patients5485514008338709110639405240083337191118
with40705240083506587124
multiple420652400835693108129144182198232
sclerosis.44505240083255771105126162188202228241
Arch47015240083375785120
Neurol.483152400834272107127161175188
2006502852400833467102137
Oct;63(10):13837.517752400834678101114149182199230260278289318347381414394053400833440
doi:39965340083387691103
10.1001/archneur.63.10.1383.41155340083346578109140176208230260281312350388423461482493528562574605636649680710744778791
48.39405440085367490
Thompson404854400833372110168208234273311
AJ,43775440083416881
Banwell447654400833568106157191207222
BL,47165440083366882
Barkhof48165440083356890120159198217
F,505154400833339
et510854400833456
al.51835440083324760
Diagnosis52615440083466193132170209235250276
of555654400833756
multiple394055400835896111134149189205240
sclerosis:42005540083275975110131169196211237250
2017447155400833468100130
revisions46225540083205587103130145183222248
of489155400833757
the49685540083226196
McDonald508555400835487133172211243259298
criteria.5404554008331536891125147162195208
Lancet394056400832964101130159181
Neurol.413356400834373109130165180193
2018;17(2):162-173.433956400833468100131143173203219253271283313344377398428458492504
49.39405740085367285
Vermersch40445740083366890148183204232264302
P,436457400833640
Czlonkowska44235740083407086124163193230281308338372
A,481357400834155
Grimaldi48875740083436581138171186225240
LM,514657400833187100
et526557400833456
al.53405740083314760
Teriflunomide54185740083336385100118135172394058400833876134149188223
versus41785840083326687115152178
subcutaneous437158400832664103135173196228267302340378405
interferon47915840083145274108129150185206243282
beta-1a50885840083397496129152182211
in531458400831553
patients53825840083387193108143181203230
with39405940083516689127
relapsing40865940083215570103142169183221260
multiple436659400835795110132148187203237
sclerosis:46235940083265873108129167193208234247
A4889594008341
randomised,49455940083215492131169227243269304343356
controlled532059400833268107128150187203218253292
phase394060400833977109136171
34126604008335
trial.4176604008321435991106119
Mult431060400835389104124
Scler.44476040083316075105126136
2014;20(6):705-716.459660400833468100131143178212232265283295328361395417449481512526
50.39406140085367287
Viglietta40406140083365291106121156178202235
V,428861400833644
Miller43456140083557085100135156
D,451461400834656
Bar-Or45836140083366990110159181
A,477761400834155
et484561400833456
al.49146140083324760
Efficacy4987614008333516986118151183217
of521761400833756
delayed-release5286614008338738912115218622524827030439406240083155082108143
dimethyl410062400833853111146168206237253
fumarate437062400831857115147168201223257
in464462400831452
relapsing-remitting47136240083215571103142169183221260283305339397412434459474512551
multiple528162400835795110132148187203237
sclerosis:55356240083275939406340083154970107133148173186
integrated41386340083155273106146166199220254293
analysis444363400833269101116148174189214
of467063400833756
the47386340083226094
phase484563400833876108134169
35026634008334
trials.5072634008322435890105131144
Ann522663400833773110
Clin53466340083375266102
Transl54586340083314781117140154
Neurol.394064400834373109130165180193
2015;2:103-18.414864400833468100130141176188218250283305335366380
doi:10.1002/acn3.148.45436440083387692104134165178209240276309336366398436471483514545581594